Elifibranor: all 23 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Phase 3
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisRecruitingNCT06016842Phase 3
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT04526665Phase 3Results posted
- Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)TerminatedNCT03883607Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic AcidCompletedNCT03124108Phase 2Results posted
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT02704403Phase 3Results posted
- Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT01694849Phase 2Results posted
- A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT06730061Phase 3
- A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.CompletedNCT06383403Phase 3
- A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.Active, not recruitingNCT05627362Phase 2
- A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single TabletCompletedNCT05564208Phase 1
- Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy ParticipantsCompletedNCT05543369Phase 1
- Elafibranor Pharmacokinetic Parameters in Elderly Healthy VolunteersCompletedNCT04171752Phase 1
- Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and IndomethacinCompletedNCT03985969Phase 1
- Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)TerminatedNCT03953456Phase 2
- Elafibranor Pharmacokinetic Parameters in Renal Impaired PatientsCompletedNCT03844555Phase 1
- Elafibranor Pharmacokinetic Parameters in Hepatic Impaired PatientsCompletedNCT03765671Phase 1
- Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy VolunteersCompletedNCT02091310Phase 1
- Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505CompletedNCT01474161Phase 1
- Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.CompletedNCT01275469Phase 2
- Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal ObesityCompletedNCT01271777Phase 2
- Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal ObesityCompletedNCT01271751Phase 2
- Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes MellitusCompletedNCT01261494Phase 2